Kornimate/medical-research-clean huggingface dataset:
esthetic outcomes of single immediate implant placement

Conditions: Gingival Recession; Bone Loss, Alveolar

Summary: a randomized controlled trial of 12-month duration to compare gingival margin location, buccal horizontal ridge dimensions, and interproximal crestal bone levels following two surgical approaches for immediate placement of implants in the esthetic zone: one involving flap elevation and another using a flapless protocol.

in the test group, the implant will be placed according to standard protocol at a position engaging the palatal wall without elevation of a mucoperiosteal flap. in the control group, intrasulcular incisions will be carried out from one tooth distal to one tooth mesial to the extraction site and full thickness flaps will be elevated with periosteal elevator, including the papillae. the implant will be placed according to standard protocol at a position engaging the palatal wall, and the flaps will be sutured using a combination of interrupted and mattress sutures. in both groups, temporary restorations will be delivered immediately after implant placement provided that the implant shows primary stability and has engaged in the bone with an insertion torque of 25ncm or more. in case of a lower insertion torque, the protocol will be abandoned, a cover screw will be placed, and a two stage implant protocol will be followed. all patients will be advised to receive a permanent restoration 6 months after surgery, if the implant is deemed to be successful.

Eligibility criteria:
inclusion criteria: * single non-restorable tooth in the anterior maxilla * intact buccal plate or \<5mm fenestration exclusion criteria: * pregnancy * current smokers \>10 cigarettes/day * parafunctional habits * malocclusion or intent of orthodontic therapy in the future * severe periodontal disease

Keywords: dental implants surgical flap esthetics alveolar process
radiotherapy in hepatocellular carcinomas after hepatectomy with narrow margin (<1 cm) and / or microvascular invasion

Conditions: HepatoCellular Carcinoma

Summary: hepatocellular carcinoma is one of ten leading cancer types worldwide and also in asia, but the five-year relative survival rate is relatively quite low1-3. for hepatocellular carcinoma treatment, current options are surgical resection, embolization chemotherapy, radiation therapy, a variety of ablation therapy, biological and gene therapy, etc. among them, the use of radiation therapy is getting more and more attention, and it is changing from the past palliative treatment to current curable treatment. from an oncologic point of view, a narrow margin \<1 cm and microvascular invasion is not safe and is often associated with higher rates of recurrence and shorter patient survival.on the other hand, it is also believed that most intrahepatic recurrences arise from multicentric carcinogenesis and are distant from the resection margin. to address this issue, the investigators are going to conduct a series of retrospective and prospective studies to investigate the effect of adjuvant radiotherapy for centrally located hepatocellular carcinoma after narrow margin (\<1 cm) hepatectomy on tumor recurrence.


Eligibility criteria:
inclusion criteria: 1. patients were pathologically diagnosed as bclc-a stage hepatocellular carcinomas, liver function were child-pugh class a or liver function changed from class b to class a after short-term liver treatment, ps scored 0-1, and accepted hepatocellular carcinomas resection (r0 resection). 2. no recurrence was found within 3-4 weeks after surgery. 3. pathologically confirmed as narrow margin (the closest distance from margin to tumor capsule (\<1 cm) and microvascular invasion was found in tumor capsule and adjacent tissues junction (material selection and pathological diagnosis were based on "standardization pathology guide of primary liver cancer 2015 edition" ). 4. postoperative radiotherapy was the only combination therapy within one month after surgery. 5. radiation range was margin radiation along and/or joint portal vessels radiotherapy. 6. no lymph node and distant metastasis before surgery. exclusion criteria: 1. patients were pathologically diagnosed as bclc-b, c, d stage hepatocellular carcinomas, liver function were child-pugh class c, ps scored ≥2. or primary liver cancer patients were pathologically diagnosed as cholangiocarcinoma or mixed type liver cancer. or patients did not accept hepatectomy. 2. patients received transcatheter arterial chemoembolization, chemotherapy, targeted medicine or other anti-cancer therapy before surgery. 3. recurrence was found within 3-4 weeks after surgery. 4. postoperative adjuvant therapy included treatment other than radiotherapy within one month after surgery. 5. radiation range involved lymph node other than portal vein area. 6. lymph node and distant metastasis were diagnosed before surgery.
clinical efficacy of amoxicillin given twice or three times a day among children with non-severe pneumonia

Conditions: Community-acquired Pneumonia

Summary: the purpose of the study is to compare the clinical efficacy of amoxicillin given twice or three times a day to children with non-severe community-acquired pneumonia.


Eligibility criteria:
inclusion criteria: * children aged between 2 and 59 months * report of respiratory complaints * presence of pulmonary infiltrate on chest x-ray taken on admission and read by the pediatrician on duty exclusion criteria: * lower chest indrawing * danger signs (inability to drink, convulsions, somnolence, central cyanosis, grunting in a calm child) * diagnosed underlying chronic diseases (anatomic abnormalities of the respiratory tract, chronic pulmonary illness besides asthma, immunological defects, progressing neurological disorders, psychomotor retardation, heart disease with clinical repercussion, hemoglobinopathy, liver or kidney disease) * severe malnutrition * other concurrent infection * hospitalization during the previous 7 days * amoxicillin or similar antibiotic use during the last 48 hours * allergy to amoxicillin * history of aspiration

Keywords: children aged under 5 years non-severe
effects of levosimendan on microcirculation in septic shock

Conditions: Septic Shock

Summary: the present study was conducted as a prospective, randomized, controlled study to: * investigate the effects of a combination of levosimendan and inhaled nitric oxide on systemic hemodynamics and microcirculation in patients with catecholamine-dependent septic shock; * test the hypothesis that levosimendan plus inhaled nitric oxide may be effective in restoring microvascular function in septic shock.

40 septic shock patients requiring norepinephrine to maintain mean arterial pressure between 65 and 75 mmhg despite adequate volume resuscitation will be enrolled in the study. after an initial hemodynamic resuscitation aimed at achieve a mean arterial pressure between 65 and 75 mmhg and a mixed venous oxygen saturation (svo2) ≥ 65%, patients will be randomly allocated to be treated with either a) intravenous administration of levosimendan 0.2 µg∙kg-1∙min-1 for 24 hrs, b)intravenous administration of dobutamine 5 µg∙kg-1∙min-1 for 36 hrs(control; each n = 20). at the end of the first 24 hrs of the study period, both groups will receive inhaled nitric oxide at the concentration of 35 ppm for further 12 hrs. in all patients norepinephrine was titrated to maintain mean arterial pressure between 65 and 75 mmhg. data from right heart catheterization and sublingual microvascular network will be obtained just before randomization (baseline) and then after 24 and 36 hours. the sublingual microvascular network will be studied using the sidestream dark field (sdf) imaging. the device will be applied on the lateral side of the tongue, in an area approximately 2-4 cm from the tip of the tongue. sequences of 10 secs from eight adjacent areas will be recorded on disk using a personal computer. these sequences will be later analyzed by an investigator blinded to the patient's diagnosis and therapy.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of septic shock * vasopressor support to maintain mean arterial pressure (map) between 65 and 75 mmhg despite adequate volume resuscitation (pulmonary artery occlusion pressure = 13-18 mmhg and central venous pressure = 8-12 mmhg) exclusion criteria: * pregnancy * age \< 18 years * ventricular outflow tract obstruction * mitral valve systolic anterior motion

Keywords: sepsis septic shock microcirculation levosimendan dobutamine inotropes inhaled nitric oxide
post-marketing safety study of autoimmune diseases following cervarix® vaccination

Conditions: Infections, Papillomavirus

Summary: the purpose of this post-marketing study is to evaluate the incidence of autoimmune diseases (aids) following females who have received at the least the first dose of cervarix® as part of their routine health care.


Eligibility criteria:
inclusion criteria: both cohorts: * have complete medical insurance coverage and pharmacy benefits. * enrolled female health plan members for at least one year prior to study entry. * age between 9 and 25 years at study entry. exposed cohort: • subjects who have received at least one dose of cervarix®, with or without any other us age-appropriate recommended vaccines. unexposed cohort: • no further specific inclusion criteria exclusion criteria: both cohorts: • subjects with a diagnostic code of any of the aid endpoints of interest during the one year prior to the index date. exposed cohort: • subjects who received any dose of gardasil® prior to the first dose of cervarix®. unexposed cohort: • subjects who receive any dose of cervarix® prior to the index date.

Keywords: autoimmune diseases hpv vaccine papillomavirus human papillomavirus hpv
benefit of a hospital intervention in patients with hepatic steatosis

Conditions: Hepatic Steatosis

Summary: the objective of this clinical trial is to determine whether a specialized consultation for controlling metabolic syndrome effectively treats hepatic steatosis in adults. the primary questions it aims to answer are: • does this specialized consultation increase the number of patients with hepatic steatosis who show improvement after one year of clinical follow-up in said consultation? the improvement of the disease will be assessed through the following parameters: * liver laboratory tests * weight loss * improvement in cholesterol and triglyceride levels. researchers will compare follow-up in the specialized consultation to standard follow-up to assess the effectiveness of the specialized consultation in treating hepatic steatosis. participants will be randomly assigned to two groups. the first group will be visited in the specialized consultation every three months for one year and will continue to receive the rest of their follow-up visits. the second group will undergo their usual follow-up visits but will not be visited in the specialized consultation.


Eligibility criteria:
inclusion criteria: * patients seen in outpatient gastroenterology clinics with hepatic steatosis. * diagnosed with hepatic steatosis through ultrasound or abdominal ct scan * mild to moderate fibrosis as assessed by elastography or fibroscan (f1-f3) or with a fibrosis-4 (fib-4) index less than 3.5. * signature of informed consent for study inclusion, either by the participant themselves or by their legal representative. exclusion criteria: * patients who do not have any hepatic imaging test conducted in the last 5 years. * conditions other than hepatic steatosis requiring gastroenterological follow-up. * abusive alcohol consumption, defined as weekly intake of \> 50 g in women and more than 70 g in men. * cognitive or affective disorders limiting the ability to cooperate with study procedures. * participation in another clinical trial involving experimental intervention during the period of this trial and/or establishing visit schedules incompatible with this trial.

Keywords: fatty liver metabolic syndrome
doxycycline and ceftriaxone in suspected early lyme neuroborreliosis

Conditions: Suspected Early Lyme Neuroborreliosis

Summary: the investigators will compare doxycycline and ceftriaxone in treatment of patients with suspected early lyme neuroborreliosis and normal csf cell count. the study hypothesis is that the efficacy and adverse effects of both antibiotics are comparable.


Eligibility criteria:
inclusion criteria: * age \>15 years * erythema migrans in 4 months period before neurologic symptoms * normal csf cell count * absence of more defined clinical symptoms or signs for cns involvement (radicular pain, meningeal signs, peripheral facial palsy). exclusion criteria: * pregnancy * lactation * allergy on doxycycline and ceftriaxone * immune deficiency.

Keywords: lyme neuroborreliosis lyme borreliosis erythema migrans doxycycline treatment ceftriaxone treatment outcome subjective symptoms
study to evaluate safety and efficacy of different doses of bimekizumab in patients with chronic plaque psoriasis

Conditions: Chronic Plaque Psoriasis

Summary: this is a phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to investigate the safety, efficacy, pharmacokinetics (pk), and pharmacodynamics (pd) of bimekizumab compared with placebo in adult subjects with moderate to severe chronic plaque psoriasis in order to guide the selection of doses and clinical indices in the phase 3 development program.


Eligibility criteria:
inclusion criteria: * subject has provided informed consent * chronic plaque psoriasis for at least 6 months prior to screening * pasi (psoriasis area and severity index) \>=12 and bsa (body surface area) \>=10% and iga (investigator's global assessment) score 3 or greater on a 5-point scale * candidates for systemic psoriasis therapy and/or phototherapy and/or chemophototherapy * female subjects must be postmenopausal, permanently sterilized or, if of childbearing potential, must be willing to use a highly effective method of contraception up till 20 weeks after last administration of study drug * male subjects with a partner of childbearing potential must be willing to use a condom when sexually active, up till 20 weeks after the last administration of study medication exclusion criteria: * subjects with erythrodermic, guttate, pustular form of psoriasis, or drug-induced psoriasis * subject has any severe, progressive and/or uncontrolled renal, hepatic, hematological, endocrine, pulmonary, cardiac, gastrointestinal or neurological disease * subject has any significant concurrent medical condition or laboratory abnormalities, as defined in the study protocol * subject taking prohibited psoriatic medications * subject receiving any live vaccines within 8 weeks prior to the baseline and subjects receiving bacillus calmette-guerin (bcg) vaccination within 1 year prior to study drug administration * subject has previously received treatment with any anti-interleukin-17 (anti-il-17) therapy or has been exposed to more than 1 biological response modifier (limited to anti-tumor necrosis factor (tnf) or il-12/23) for psoriatic arthritis or psoriasis prior to the baseline * subject has any current sign or symptom that may indicate an active infection (except for common cold)

Keywords: psoriasis chronic plaque psoriasis bimekizumab
gender related coping and survivorship for genitourinary cancers

Conditions: Bladder Cancer

Summary: this research is being done to learn more about coping and survivorship of women with bladder cancer, specifically regarding psychosocial distress and sexual dysfunction. this study is a non-therapeutic study and will randomize participants to a standard of care group and education group. patients in both groups will be asked to complete surveys regarding their mood and sexual function. patients in the intervention group will be asked to complete attendance diaries regarding educational and support services utilized. participants' clinical data will also be collected.

the gender related coping and survivorship study for genitourinary cancers is focused on providing patients with additional education to promote sexual function in female bladder cancer patients with the aim to help decrease demoralization and sexual dysfunction. patients receiving a cystectomy and patients not receiving a cystectomy will be randomized separately into an additional education or standard of care group. the additional education consists of asking patients to attend the women and bladder cancer educational series, women's bladder cancer support group meetings, referrals to other support services, receiving supplemental handouts and treating physician led counseling incorporated into standard of care visits. all participants will be asked to complete the demoralization scale-ii and female sexual function index at baseline, one-month following treatment, three-months following treatment, six-months following treatment, and one year following treatment. patients randomized to the additional education group will also be asked to complete an attendance diary one-month following treatment, three-months following treatment, six-months following treatment, and one year following treatment.

Eligibility criteria:
inclusion criteria: * females with bladder cancer * willing to answer surveys regarding their psychosocial health and sexual health exclusion criteria: * not undergoing either active treatment or active surveillance (i.e. patients on hospice care) * patients with cognitive impairments * women who are pregnant

Keywords: female adult genitourinary cancers
the development of a gamified web-based pain management program (gap) for community-dwelling older adults with chronic pain

Conditions: Chronic Pain Syndrome

Summary: pain management in older adults: pain significantly impacts the well-being of older adults, often leading to diminished physical abilities and a reduced quality of life. despite this, pain management remains suboptimal, with concerns about medication side effects and a tendency to view pain as a natural aspect of aging. consequently, many seniors are hesitant to use painkillers. as an alternative, non-pharmacological strategies such as educational programs, physical activity, massage, relaxation techniques, and music therapy are gaining traction. innovative non-drug solutions: to improve participation in non-medication pain relief methods, we suggest incorporating gaming elements into these programs (gap). originating in digital media in 2008, gamification has since spread across various industries. it involves adding game-like elements to activities to boost engagement, experience, and motivation. project goals: the aims of this initiative include creating a web-based gamified pain management program (gap), engaging older adults with chronic pain in the development of gap, and gathering their feedback on the program's effectiveness.


Eligibility criteria:
inclusion criteria: * aged 60 or above * can understand cantonese * scored \>6 in the abbreviated mental test; a cut-off point of 6 is valid for differentiating between normal and abnormal cognitive functions in geriatric clients * have a history of non-cancer pain in the past 6 months * have a pain score of at least 2 on the numeric rating scale * able to take part in light exercise and stretching * owns a smartphone and can access the internet exclusion criteria: * have severe visual and/or auditory deficits that affect that seeing and hearing * have a serious organic disease or malignant tumor * have a mental disorder diagnosed by neurologists or psychiatrists * had a surgical treatment in the past two months * experienced drug addiction
a research study of how the medicine nnc0480-0389 taken with semaglutide works in the body of healthy japanese men

Conditions: Healthy Volunteers Type 2 Diabetes

Summary: this study looks at how the new medicine called nnc0480-0389 works in the body of japanese men when it is given together with semaglutide. participants will get nnc0480-0389 and semaglutide or 2 doses of placebo - which treatment participants get is decided by chance. nnc0480-0389 is a new medicine that has not been previously approved. it means that the medicine has not yet been approved by the health authorities. semaglutide is a newly approved antidiabetic medicine that helps to lower blood sugar levels in patients with type 2 diabetes. nnc0480-0389 is being developed to be given together with semaglutide.nnc0480-0389 targets a different part of the system that regulates sugar levels in the body than semaglutide. therefore, it is expected that together nnc0480-0389 and semaglutide will more effectively lower sugar levels in the blood. participants will get 2 injections of the study medicine. it will be injected with a needle into a skin fold on participants' stomach. the study will last for a maximum of 72 days. participants will have 10 scheduled visits with the study doctor. for 1 of the visits participants will stay at the clinic for 6 days (5 nights).the study includes blood sampling.


Eligibility criteria:
inclusion criteria: * male aged 20-55 years (both inclusive) at the time of signing the informed consent. * both parents of japanese descent. * body mass index between 20.0 kg/m\^2 and 24.9 kg/m\^2 (both inclusive). * considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. exclusion criteria: * any disorder which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol. * glycated haemoglobin (hba1c) greater than or equal to 6.5% (48 mmol/mol) at screening. * use of prescription medicinal products or non-prescription drugs, except routine vitamins, occasional use of acetaminophen, ibuprofen and acetylsalicylic acid, or topical medication not reaching systemic circulation within 14 days prior to the day of screening. * presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal, or endocrinological conditions.
factors influencing hemoglobin variability and its association with mortality in hemodialysis patients

Conditions: Hemodialysis-Induced Symptom

Summary: the aim of the study is to investigate the factors influencing hemoglobin variability with inflammatory and nutritional parameters and its associations with all-cause mortality among hemodialysis patients.

fluctuation in hemoglobin levels that is known as hemoglobin variability during treatment with esa is a well-documented phenomenon. several factors have been found to affect hemoglobin variability, including drug related, such as pharmacokinetic parameters, patient-related differences in demographic characteristics and factors affecting clinical status, as well as clinical practice guidelines, treatment protocols and reimbursement policies. inflammation is also an important factor associated with hemoglobin variability, and the consequences of persistent inflammatory activity are far-reaching in affected patients. in present study, the factors influencing hemoglobin variability with inflammatory and nutritional parameters and its associations with all-cause mortality among hemodialysis patients are investigated.

Eligibility criteria:
inclusion criteria: * age \>18 * on chronic hemodialysis treatment exclusion criteria: * all patients had a minimum of six hemoglobin measurements within a 6- month period, and they were excluded if they received a kidney transplant during this period or those who had blood transfusions during the baseline period. * patients with serum ferritin\<100 μg/l were also excluded from the study because of reimbursement of our country.

Keywords: hemodialysis hemoglobin variability mortality nutrition inflammation